Vertex and Republic of Ireland Reach Agreement on Reimbursement for Triple Combination Therapy
5 New Drug Approvals the FDA Gave Top Priority
Long-awaited cystic fibrosis drug could turn deadly disease into a manageable condition
New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients
5,000 Expected to Attend Cystic Fibrosis Conference, NACFC 2019, in Nashville
Kalydeco’s Efficacy Tied to Phosphorylation Levels of CFTR Protein, Study Suggests
FDA to Review Elexacaftor, Tezacaftor, Ivacaftor Combo for Cystic Fibrosis
Kalydeco’s Safety and Benefits Studied in CF Patients with Severe Lung Disease
FDA Approves Kalydeco for Treatment of 6- to 12-month-old Infants with Cystic Fibrosis
Vertex Pharma (VRTX) Receives Approval for SYMDEKO in Australia to Treat Underlying Cause of CF
